Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michaele Oostendorp

Internal Medicine Riverview, MI Doctor of Osteopathy

NPI 1154329423 CMS profile 187827

14700 King Rd, Ste A, Riverview, MI 48193

Open in the dashboard

General payments

$8,982

568 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michaele Oostendorp of Riverview, MI is reported in the CMS Open Payments database as having received $8,982 across 568 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,057 63
2024 General $1,406 81
2023 General $1,746 103
2022 General $1,899 113
2021 General $1,738 121
2020 General $592 44
2019 General $545 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michaele Oostendorp
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Michaele Oostendorp were reported at $1,057. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Michaele Oostendorp Internal Medicine median Middle half National median
2019 $545 $159 $48–$570 $163
2020 $592 $119 $33–$402 $114
2021 $1,738 $135 $37–$521 $132
2022 $1,899 $141 $42–$496 $149
2023 $1,746 $149 $45–$519 $160
2024 $1,406 $154 $47–$537 $164
2025 $1,057 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,677 134 payments
  2. AbbVie, Inc. $1,269 80 payments
  3. Lilly USA, LLC $903 68 payments
  4. Astellas Pharma US Inc $675 32 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $447 23 payments
  6. Amgen Inc. $406 24 payments
  7. GlaxoSmithKline, LLC. $392 26 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $391 25 payments
  9. Pfizer Inc. $341 22 payments
  10. AstraZeneca Pharmaceuticals LP $281 17 payments
  11. Other $2,199 117 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,882 567 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. RYBELSUS $947 78 payments
  2. Ozempic $923 86 payments
  3. UBRELVY $511 31 payments
  4. MOUNJARO $412 34 payments
  5. XIFAXAN $391 25 payments
  6. Wegovy $378 23 payments
  7. VRAYLAR $378 26 payments
  8. JARDIANCE $360 25 payments
  9. MYRBETRIQ $337 19 payments
  10. TRELEGY ELLIPTA $326 21 payments
  11. Other $6,422 386 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 135 drugs

Part D claims

6,580

Median for Internal Medicine: 777

Drug cost

$549,106

Median for Internal Medicine: $73,373

Branded share of claims

26.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 64 $81,297
Jardiance Empagliflozin Brand 65 $65,902
Eliquis Apixaban Brand 50 $63,584
Ozempic Semaglutide Brand 48 $58,192
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 39 $44,017
Xarelto Rivaroxaban Brand 26 $21,517
Januvia Sitagliptin Phosphate Brand 20 $18,206
Farxiga Dapagliflozin Propanediol Brand 13 $16,913
Trulicity Dulaglutide Brand 11 $15,286
Linzess Linaclotide Brand 11 $12,409

The 10 drugs with the highest cost, of 135 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$145,909

Of which drugs: $282

Medicare patients

419

Average age 75

Services billed

2,385

328 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Heart failure 50%
Osteoporosis 38%
Diabetes 34%
Ischemic heart disease 34%
COPD 29%
Chronic kidney disease 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 36 53 $265

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
$151 — —
JARDIANCE
$142 65 —
MOUNJARO
$113 64 —
ZEPBOUND
$98 — —
VRAYLAR
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

568 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record